Researchers in Pittsburgh are planning one of the largest tests yet of whether GLP-1 drugs can treat addiction — and the first designed to measure what that would mean for people’s lives beyond the clinic. The trial will give weekly semaglutide, the active ingredient in Wegovy and Ozempic, to adults with alcohol use disorder, opioid use disorder or both, and follow not only their drinking and drug use but also their employment, housing stability, health care use and contact with the criminal justice system. It was announced on October 13, 2026 and is due to start enrolling in early 2027.
How the trial will work
The study plans to enroll up to 1,200 adults in Allegheny County, Pennsylvania, focusing on people at elevated risk of involvement with the justice system. Half will be randomly assigned to receive weekly semaglutide injections on top of their existing addiction care; the other half will continue standard care without the drug. Participants will be followed for 52 weeks. The primary question is whether semaglutide reduces alcohol and opioid use and cravings. The broader questions are whether it improves the outcomes that shape a person’s life, and whether any gains in work or justice involvement come from reduced substance use or through other routes.
Who is behind it
The trial is organized by the Center for Addiction Science, Policy and Research (CASPR), a nonprofit focused on GLP-1 drugs for addiction, with the Allegheny County Department of Human Services. It is funded by a $13.3 million grant from Arnold Ventures. UPMC Western Psychiatric Hospital’s addiction medicine service will be the lead clinical site, and the principal investigator listed in the trial registry is J. Travis Donahoe of the University of Pittsburgh, with co-investigators from UC San Diego, MIT and the county.
The unusual part: real-world data
Most addiction trials measure drinking days, drug tests and self-reported cravings over a few months. This one will draw on the county’s linked administrative records, which connect data on jail bookings, employment, housing services and health care. That allows researchers to see, objectively and over a full year, whether people who receive the drug are arrested less, keep jobs longer or avoid homelessness — outcomes that matter enormously to patients and to public budgets, but that are rarely measured in medical research.
Why GLP-1 drugs might help addiction
The idea came partly from patients. Many people taking semaglutide or tirzepatide for weight or diabetes reported that they lost interest in alcohol, and sometimes in smoking or other habits. GLP-1 receptors are found in brain areas involved in reward and motivation, and animal studies show the drugs dampen the release of dopamine triggered by alcohol and other drugs. Large health-record studies have linked GLP-1 use to fewer alcohol- and opioid-related problems, and small randomized trials have found reductions in heavy drinking and in cravings. But the human evidence remains limited, and none of these drugs is approved to treat addiction.
Why the scale matters
Small early trials can overestimate benefits, and they rarely include the people most affected by addiction: those with unstable housing, criminal records or several conditions at once. A large, randomized study in that population, using objective records, is far more likely to show whether the early signals hold up in the real world. If the drug works, the data on employment and justice involvement could also make a strong case for public investment, since the costs of untreated addiction fall heavily on jails, emergency rooms and social services.
Where it fits with existing treatment
Proven treatments for addiction already exist but are badly underused. For opioid use disorder, buprenorphine and methadone sharply reduce overdose deaths; for alcohol use disorder, drugs such as naltrexone and acamprosate help many patients, yet only a small fraction of people who could benefit receive any medication. In this trial, semaglutide is added on top of existing care rather than replacing it. The aim is to see whether it provides extra benefit, not to substitute for treatments that work.
The caveats
There are no results yet, and the trial registry lists the protocol as still in development, so details could change. Semaglutide causes nausea and other digestive side effects, which may be harder to tolerate for people who are already unwell or underweight, and appetite loss is not always desirable in this population. Keeping participants engaged for a year is difficult in any addiction study. And even if semaglutide reduces substance use, the effects on employment and arrests may be modest, because those outcomes depend on many factors beyond any medication.
What comes next
Enrollment is expected to begin in early 2027, with results likely a year or more after that. Several other trials of GLP-1 drugs for alcohol, opioid and nicotine addiction are under way, including at the VA. Together, they should establish within a few years whether these drugs earn a place in addiction treatment. In the meantime, anyone struggling with alcohol or opioids should know that effective treatments are available now; a doctor, pharmacist or the national helpline (in the US, 1-800-662-4357) can help. This is research news, not medical advice.